Search the GHTC website

Global health R&D delivers for Maine

US government investment in global health R&D has delivered

$6.1 million
to Maine research institutions
Maine's top USG-funded global health R&D institutions

Maine's top USG-funded global health R&D institutions

The Jackson Laboratory
$5.3 million
$495 thousand
MDI Biological Laboratory (formerly Mount Dessert Island Biological Laboratory)
$211 thousand

Maine's top areas of global health R&D by USG funding

Neglected tropical diseases
Helminth infections (Worms & Flukes)
Multi-disease/health area R&D
Global health R&D at work in Maine

The Hallowell-based nonprofit MCD Global Health is a key implementing partner of an initiative on Bioko Island, Equatorial Guinea that carried out clinical trials of a promising new malaria vaccine. Unlike existing malaria vaccines—called sub-unit vaccines—that use a specific protein from the malaria parasite to induce an immune response, the vaccine candidate, PfSPZ, is a whole-parasite vaccine, meaning it uses a deactivated full malaria parasite to maximize the spectrum of the immune response it produces. The vaccine received fast track status from US Food and Drug Administration, which will enable it to receive expedited review once it completes clinical development.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PMI/ Moses Senesie